Skip to content

Study · Randomized controlled trial · 2019

5 results

Glycaemic benefit of iGlarLixi in insulin-naive type 2 diabetes patients with high HbA1c or those with inadequate glycaemic control on two oral antihyperglycaemic drugs in the LixiLan-O randomized trial.

Davies MJ, Russell-Jones D, Barber TM, Lavalle-González FJ, Galstyan GR, Zhu D, Baxter M, Dessapt-Baradez C, McCrimmon RJ

Diabetes, obesity & metabolism18 Jun 2019Cited by 15 (Europe PMC)

PMID31124299 (opens in a new tab)PMCIDPMC6772132 (opens in a new tab)DOI10.1111/dom.13791 (opens in a new tab)PepBankPUB-31124299
Read at sourcePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes and baseline HbA1c ≥9%, iGlarLixi reduced HbA1c more than insulin glargine (2.9% versus 2.5%).

    In plain wordsIn patients with high baseline HbA1c, iGlarLixi reduced HbA1c more than insulin glargine.

    Peptide
    Lixisenatide
    Outcome
    DecreaseHbA1c reduction, baseline HbA1c ≥9%
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    LS mean HbA1c reduction
    2.9%
    iGlarLixi, baseline HbA1c >=9%
    LS mean HbA1c reduction
    2.5%
    insulin glargine, baseline HbA1c >=9%

    Source sentences

    Summary
    Treatment with iGlarLixi resulted in significantly greater reduction in least squares mean HbA1c compared to treatment with iGlar or Lixi alone in both subgroups (group 1: 2.9%, 2.5%, 1.7% and group 2: 1.5%, 1.2%, 0.7%, respectively).
    1 context sentence
    Summary · context
    In this post hoc analysis of the randomized controlled LixiLan-O trial in insulin-naive patients with type 2 diabetes mellitus (T2DM) not controlled with metformin, with or without a second oral antihyperglycaemic drug (OAD),
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with inadequate control on two oral drugs, iGlarLixi reduced HbA1c more than insulin glargine (1.5% versus 1.2%).

    In plain wordsIn patients uncontrolled on two oral drugs, iGlarLixi reduced HbA1c more than insulin glargine.

    Peptide
    Lixisenatide
    Outcome
    DecreaseHbA1c reduction, inadequate control on two oral drugs
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    LS mean HbA1c reduction
    1.5%
    iGlarLixi, inadequate control on two OADs
    LS mean HbA1c reduction
    1.2%
    insulin glargine, inadequate control on two OADs

    Source sentences

    Summary
    Treatment with iGlarLixi resulted in significantly greater reduction in least squares mean HbA1c compared to treatment with iGlar or Lixi alone in both subgroups (group 1: 2.9%, 2.5%, 1.7% and group 2: 1.5%, 1.2%, 0.7%, respectively).
    1 context sentence
    Summary · context
    In this post hoc analysis of the randomized controlled LixiLan-O trial in insulin-naive patients with type 2 diabetes mellitus (T2DM) not controlled with metformin, with or without a second oral antihyperglycaemic drug (OAD),
  3. 03HumanRandomized controlled trialEfficacy outcome

    In both diabetes subgroups, iGlarLixi mitigated weight gain compared with insulin glargine alone.

    In plain wordsIn both diabetes subgroups, iGlarLixi limited weight gain compared with insulin glargine alone.

    Peptide
    Lixisenatide
    Outcome
    DecreaseWeight gain
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Target HbA1c less than 7% was achieved in more than 70% of patients using iGlarLixi in both subgroups, while mitigating the weight gain observed with use of iGlar alone.
    1 context sentence
    Summary · context
    In this post hoc analysis of the randomized controlled LixiLan-O trial in insulin-naive patients with type 2 diabetes mellitus (T2DM) not controlled with metformin, with or without a second oral antihyperglycaemic drug (OAD),
  4. 04HumanNon-randomized trialEfficacy outcome

    In diabetes patients with baseline HbA1c ≥9%, lixisenatide alone reduced HbA1c by 1.7%.

    In plain wordsIn diabetes patients with high baseline HbA1c, lixisenatide alone reduced HbA1c by 1.7% from baseline.

    Peptide
    Lixisenatide
    Outcome
    DecreaseLixisenatide-alone HbA1c reduction, baseline HbA1c ≥9%
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    LS mean HbA1c reduction
    1.7%
    lixisenatide alone, baseline HbA1c >=9%

    Source sentences

    Summary
    Treatment with iGlarLixi resulted in significantly greater reduction in least squares mean HbA1c compared to treatment with iGlar or Lixi alone in both subgroups (group 1: 2.9%, 2.5%, 1.7% and group 2: 1.5%, 1.2%, 0.7%, respectively).
    1 context sentence
    Summary · context
    In this post hoc analysis of the randomized controlled LixiLan-O trial in insulin-naive patients with type 2 diabetes mellitus (T2DM) not controlled with metformin, with or without a second oral antihyperglycaemic drug (OAD),
  5. 05HumanNon-randomized trialEfficacy outcome

    In diabetes patients inadequately controlled on two oral drugs, lixisenatide alone reduced HbA1c by 0.7%.

    In plain wordsIn diabetes patients uncontrolled on two oral drugs, lixisenatide alone reduced HbA1c by 0.7% from baseline.

    Peptide
    Lixisenatide
    Outcome
    DecreaseLixisenatide-alone HbA1c reduction, inadequate control on two oral drugs
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    LS mean HbA1c reduction
    0.7%
    lixisenatide alone, inadequate control on two OADs

    Source sentences

    Summary
    Treatment with iGlarLixi resulted in significantly greater reduction in least squares mean HbA1c compared to treatment with iGlar or Lixi alone in both subgroups (group 1: 2.9%, 2.5%, 1.7% and group 2: 1.5%, 1.2%, 0.7%, respectively).
    1 context sentence
    Summary · context
    In this post hoc analysis of the randomized controlled LixiLan-O trial in insulin-naive patients with type 2 diabetes mellitus (T2DM) not controlled with metformin, with or without a second oral antihyperglycaemic drug (OAD),

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT02058147

Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM

Sanofin = 1,170Feb 2014 to Jun 2015

Type 2 Diabetes

Trial pageClinicalTrials.govUpdated 9 May 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.